The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study

被引:32
|
作者
Bahadir, Aysenur [1 ]
Kurucu, Nilgun [2 ]
Kadioglu, Mine [3 ]
Yenilmez, Engin [4 ]
机构
[1] Karadeniz Tech Univ, Sch Med, Dept Pediat Hematol, Trabzon, Turkey
[2] Ankara Oncol Hosp, Dept Pediat Oncol, Ankara, Turkey
[3] Karadeniz Tech Univ, Sch Med, Dept Pharmacol, Trabzon, Turkey
[4] Karadeniz Tech Univ, Sch Med, Dept Histol, Trabzon, Turkey
关键词
Doxorubicin; Nitric oxide; Nitric oxide synthase inhibitors; HEART-FAILURE; RAT-HEART; SYNTHASE; CARDIOMYOPATHY; DYSFUNCTION; ADRIAMYCIN; TOXICITY; SUPEROXIDE; ERDOSTEINE; PREVENTION;
D O I
10.4274/Tjh.2013.0013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We evaluated the myocardial damage in rats treated with doxorubicin (DOX) alone and in combination with nitric oxide synthase (NOS) inhibitors. Materials and Methods: Twenty-four male Sprague Dawley rats (12 weeks old, weighing 262 +/- 18 g) were randomly assigned into 4 groups (n=6). Group I was the control group. In Group II, rats were treated with intraperitoneal (ip) injections of 3 mg/kg DOX once a week for 5 weeks. In Group III, rats received weekly ip injections of 30 mg/kg L-NAME (nonspecific NOS inhibitor) 30 min before DOX injections for 5 weeks. In Group IV, rats received weekly ip injections of 3 mg/kg L-NIL (inducible NOS inhibitor) 30 min before DOX injections for 5 weeks. Rats were weighed 2 times a week. At the end of 6 weeks, hearts were excised and then fixed for light and electron microscopy evaluation and tissue lipid peroxidation (malondialdchyde). Blood samples were also obtained for measuring plasma lipid peroxidation. Results: Weight loss was observed in Group II, Group III, and Group IV. Weight loss was statistically significant in the DOX group. Findings of myocardial damage were significantly higher in animals treated with DOX only than in the control group. Histopathological findings of cardiotoxicity in rats treated with DOX in combination with L-NAME and L-NIL were not significantly different compared with the control group. The level of plasma malondialdehyde in the DOX group (9.3 +/- 3.4 mu mol/L) was higher than those of all other groups. Conclusion: Our results showed that DOX cardiotoxicity was significantly decreased when DOX was given with NO synthase inhibitors.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 50 条
  • [41] Doxorubicin-induced cardiotoxicity and risk factors
    Belger, Carl
    Abrahams, Carmelita
    Imamdin, Aqeela
    Lecour, Sandrine
    IJC HEART & VASCULATURE, 2024, 50
  • [42] DEXRAZOXANE IN THE PREVENTION OF DOXORUBICIN-INDUCED CARDIOTOXICITY
    SEIFERT, CF
    NESSER, ME
    THOMPSON, DF
    ANNALS OF PHARMACOTHERAPY, 1994, 28 (09) : 1063 - 1072
  • [43] Amelioration of doxorubicin-induced cardiotoxicity by resveratrol
    Al-Harthi, Sameer E.
    Alarabi, Ohoud M.
    Ramadan, Wafaa S.
    Alaama, Mohamed N.
    Al-Kreathy, Huda M.
    Damanhouri, Zoheir A.
    Khan, Lateef M.
    Osman, Abdel-Moneim M.
    MOLECULAR MEDICINE REPORTS, 2014, 10 (03) : 1455 - 1460
  • [44] Prevention of doxorubicin-induced cardiotoxicity by melatonin
    Eser Öz
    Deniz Erbaş
    H. Selçuk Sürücü
    Ersel Düzgün
    Molecular and Cellular Biochemistry, 2006, 282 : 31 - 37
  • [45] Myofilament changes in doxorubicin-induced cardiotoxicity
    Goncalves Rodrigues, P.
    Miranda-Silva, D.
    Barros, C.
    Handami, N.
    Linke, W.
    Falcao-Pires, I.
    Leite-Moreira, A. F.
    EUROPEAN HEART JOURNAL, 2014, 35 : 663 - 663
  • [46] Empagliflozin attenuates doxorubicin-induced cardiotoxicity
    Baris, Veysel Ozgur
    Dincsoy, Adnan Berk
    Gedikli, Esra
    Zirh, Selim
    Muftuoglu, Sevda
    Erdem, Aysen
    TOXICOLOGY RESEARCH, 2023, 12 (05) : 998 - 998
  • [47] Prevention of doxorubicin-induced cardiotoxicity by melatonin
    Öz, E
    Erbas, D
    Sürücü, HS
    Düzgün, E
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2006, 282 (1-2) : 31 - 37
  • [48] Cardiomyocyte death in doxorubicin-induced cardiotoxicity
    Zhang, Yi-Wei
    Shi, Jianjian
    Li, Yuan-Jian
    Wei, Lei
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2009, 57 (06) : 435 - 445
  • [49] Prevention of doxorubicin-induced cardiotoxicity by benfotiamine
    Taylor, Justin R.
    Harames, Kyra
    CANCER RESEARCH, 2023, 83 (07)
  • [50] Transcriptional analysis of doxorubicin-induced cardiotoxicity
    Yi, XM
    Bekeredjian, R
    DeFilippis, NJ
    Siddiquee, Z
    Fernandez, E
    Shohet, RV
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (03): : H1098 - H1102